Literature DB >> 6013238

Characterization of neocarzinostatin.

H Maeda, K Kumagai, N Ishida.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 6013238

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  7 in total

1.  Partial sequence of the tyrosine region of neocarzinostatin.

Authors:  C B Glaser; H Maeda; J Meienhofer; H D Niall
Journal:  Experientia       Date:  1972-07-15

Review 2.  Anticancer activity of natural and synthetic acetylenic lipids.

Authors:  Valery M Dembitsky
Journal:  Lipids       Date:  2006-10       Impact factor: 1.880

3.  Biogenesis of an antitumor antibiotic protein, neocarzinostatin.

Authors:  K Kudo; M Kikuchi; N Ishida
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

4.  Preparation of succinyl neocarzinostatin.

Authors:  H Maeda
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

5.  Mechanism of accumulation of the antitumor protein antibiotic neocarzinostatin in bladder tissue: intravenous administration, urinary excretion, and absorption into bladder tissue.

Authors:  H Maeda; S Sakamoto; J Ogata
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

6.  Clinical pharmacology of the anticancer polypeptide neocarzinostatin.

Authors:  S W Hall; J Knight; A Broughton; R S Benjamin; E McKelvey
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin. Theoretical considerations behind a two-compartment model for continuous infusion via an internal carotid artery.

Authors:  H Maeda; Y Sano; J Takeshita; Z Iwai; H Kosaka; T Marubayashi; Y Matsukado
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.